Norgine B.V. Announces New European Healthcare Subsidiary To Strengthen Its Consumer Healthcare Portfolio

Amsterdam, The Netherlands (ots/PRNewswire) - Norgine B.V. ("Norgine"), today announced the establishment of a wholly-owned subsidiary, Norgine Healthcare B.V. ("Norgine Healthcare"), which will be dedicated to consumer healthcare.

To view the Multimedia News Release, please click: https://www.multivu.com/players/uk/8822051-norgine-bv-announces-european-healthcare-subsidiary/

Norgine Healthcare will drive Norgine's consumer healthcare business, including the MOVICOL® franchise, a portfolio of laxatives for the treatment of chronic constipation that currently helps approximately 8 million patients a year around the world. [1]

ThenewsubsidiarywillbeheadedbyEricAlsac,whoiscurrentlyGeneralManagerofNorgineTheNetherlands.

NorgineHealthcareB.V.willassumeimmediatecontrolofNorgine'sexistingconsumerhealthcarefranchises.Itwillalsobuildabroaderconsumerhealthcarebusinesswiththeacquisitionofnew,transformativebrandsthatwillhelptostrengthenitsofferingasaleadingEuropeanpharmaceuticalcompanyandbenefitmorepatients.NorgineB.V.willcontinuetofocusonspecialitypharmaceuticalbrandstoaddresshighlytargeted,unmetmedicalneeds.

PeterStein,ChiefExecutiveOfficerofNorginesaid,"TheestablishmentofNorgineHealthcareB.V.willhelpustoincreasethevalueofNorgine'scurrentportfolioofhealthcareconsumerbrandsandstrengthenourcommitmenttobringingnewtransformativeproductstopatientsacrosstheworld."

ChristopherBath,ChiefOperatingOfficerofNorginesaid,"Aswellasmeetingtheneedsofpatientstomorrowthroughthedevelopmentofinnovativeproducts,wearecommittedtomaximisingthepotentialofourcurrentportfolioofbrandsthatalreadyhelpmillionsofpatientsaroundtheworld."

EricAlsac,GeneralManagerofNorgineHealthcareB.V.said,"Thisisareallyexcitingopportunityforustoensurethatourconsumerfocusedbrandsreceivetheattentionthattheydeservesothatwecanbetterservetheneedsofourpatients."

NorgineHealthcareB.V.willbefullyoperationalfrom1stDecember2020andwillbebasedinAmsterdam,TheNetherlands.

AboutNorgine

NorgineisaleadingEuropeanspecialistpharmaceuticalcompanythathasbeenbringingtransformativemedicinestopatientsforoveracentury.Ourcommitmenttotransformingpeople'slivesdriveseverythingwedoandourEuropeanexperience,fullyintegratedinfrastructureandexceptionalpartnershipapproachenablesustoquicklyapplycreativesolutionstobringlife-changingmedicinestopatientsthattheymaynototherwisebeabletoaccess.Norgineisproudtohavehelped22millionpatientsaroundtheworldin2019andgeneratedmorethanEUR419millioninnetproductsales,agrowthof6%over2018.

Norginehasadirectpresencein12Europeancountries,aswellasAustraliaandNewZealand.Wealsohaveastrongglobalnetworkofpartnershipsinnon-Norginemarkets.Weareaflexibleandfullyintegratedpharmaceuticalbusiness,withmanufacturing(Hengoed,WalesandDreux,France),thirdpartysupplynetworksandsignificantproductdevelopmentcapabilities,inadditiontooursalesandmarketinginfrastructure.Thisenablesustoacquire,developandcommercialisespecialistandinnovativeproductsthatmakearealdifferencetothelivesofpatientsaroundtheworld.

In2012,NorgineestablishedNorgineVentures,acomplementarybusinesswhichsupportsinnovativehealthcarecompaniesthroughtheprovisionofdebt-likefinancinginEuropeandtheUS.Formoreinformation,pleasevisitwww.norgineventures.com

AboutMOVICOL®

MOVICOL®isalaxative,thefirstpolyethyleneglycolpreparation,indicatedforthetreatmentofchronicconstipationinadults,adolescents,theelderlyandchildren.MOVICOL®isalsoeffectiveinresolvingfaecalimpaction,definedasrefractoryconstipationwithfaecalloadingoftherectumand/orcolon.[1][2]

MOVICOL®wasfirstlaunchedin1995andoverthepast25yearstheMOVICOL®franchisehascontinuedtoevolvetomeetpatients'needs.

MOVICOL®iscurrentlymarketedinEuropebyNorgineB.V.andwasalsomadeavailableinJapanbyEAPharmaCo.,Ltdin2018.

Followus@norgine

References

[1] MOVICOL® Summary of Product Characteristics. Available at https://www.medicines.org.uk/emc/medicine/1244/SPC/Movicol+13.8g+sachet,+powder+for+oral+solution/#gref Accessed November 2020

[2] MOVICOL® Paediatric Plain, Summary of Product Characteristics. Available at https://www.medicines.org.uk/emc/product/52/smpc#gref Accessed November 2020

Video - https://mma.prnewswire.com/media/1345522/PeterStein.mp4

Logo - https://mma.prnewswire.com/media/597589/Norgine_Logo.jpg

Rückfragen & Kontakt:

Contact:
Clara Bentham +44 (0)1895 826654 or +44 (0)7734 367883
Eleni Fistikaki +44 (0)1895826227 or +44 (0)7825 389477
contact@norgine.com

ORIGINAL APA-OTS TEXT - THE INFORMATION CONTAINED IN THIS PRESS RELEASE IS SUBJECT TO THE EXCLUSIVE RESPONSIBILITY OF THE ISSUER | PRN0004